Skip to main content
An official website of the United States government
Email

2022 Alliance for Nanotechnology in Cancer Principal Investigators’ Meeting

The 2022 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting was held virtually on October 18–19, 2022. The meeting gathered the Alliance investigators and collaborators to present their recent research results as well as to discuss emerging opportunities in cancer nanotechnology. The scientific sessions included:

  • Cancer interventions enabled by new material designs;
  • Novel cancer therapies based on nanotechnology; and
  • Immunotherapies and vaccines.

The meeting also featured panel discussions on topics “What will be the next nano-drug approved by FDA?” and “Can nanotechnology aid in combating cancer metastasis?”

Agenda

Day 1: October 18, 2022
Time Session
9–10 a.m.

Join Meeting—Computer Check
10–10:20 a.m.

Welcome and Introduction

Janet Eary, M.D., Associate Director, Cancer Imaging Program (CIP), DCTD, NCI
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI
10:20–11 a.m.

Plenary Presentation

Molly S Shoichet, Ph.D., University of Toronto

Session I: Cancer Interventions Enabled By New Material Designs (Part 1)

Moderator: Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI
11–11:20 a.m.

The Tumor Microenvironment In Nanoparticle Delivery and Function

Zaver, Bhujwalla, Ph.D., Johns Hopkins University
11:20–11:40 a.m.

Imaging of Nanotherapeutic Drug Action

Presented by Miles Miller, Ph.D., Massachusetts General Hospital
PI Ralph Weissleder, M.D., Ph.D., Massachusetts General Hospital
11:40–Noon

Copper-Depleting Nanotheranostics For Treating Triple Negative Breast Cancer

Jianghong Rao, Ph.D., Stanford University
Noon–12:20 p.m.

In Situ Cancer Cell Specific Biomineralization To Overcome Nanoparticle Delivery Barriers and Sensitize Pancreatic Cancer To Radiotherapy

Konstantin Sokolov, Ph.D., University of Texas MD Anderson Cancer Center
12:20–12:40 p.m.

Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles For Understanding And Overcoming Barriers To Drug Delivery In Invasive Glioblastoma

Dmitri Simberg, Ph.D., University of Colorado Denver
12:40–1 p.m.

Lunch Break

Session II: Discussion Panel: What Will Be The Next Nano-Drug Approved By FDA?

Moderator: Andrew Wang, M.D., UT Southwestern Medical Center
1:10–2:10 p.m.

Panel:

  • Andre Nel, M.D., Ph.D., University Of California, Los Angeles
  • Aleks Radovic-Moreno, Ph.D., Longwood Fund
  • Stephan Stern, Ph.D., DABT, Nanotechnology Characterization Laboratory

Session III: Novel Cancer Therapies Based On Nanotechnology

Moderator: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
2:10–2:30 p.m.

Ultrasmall Particle-Based Solutions For Inducing Ferroptosis And Improving Antitumor Immune Responses In Cancer

Michelle Bradbury, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
2:30–2:50 p.m.

Development Of Multifunctional Drug And Immune Modulator Delivery Nanoparticles For The Treatment Of Cancer Patients With Comorbid Atherosclerosis

Lily Yang, M.D., Ph.D., Emory University
2:50–3:10 p.m.

Nanodelivery Platform For Antibody Drugs Targeting NHL

Masakazu Kamata, Ph.D., University of Alabama at Birmingham
3:10–3:30 p.m.

Towards Translation Of MU-CN29: New Therapeutic Nanoparticle For Drug Resistant NSCLC

Raghuramann Kannan, M.D., University of Missouri-Columbia
3:30–3:45 p.m.

Break
3:45–4:05 p.m.

Targeted Therapeutics For Ovarian Cancer And Its Microenvironment—Treatment And Theoretical Modeling

Gabriel Lopez-Berestein, M.D., University Of Texas MD Anderson Cancer Center
4:05–4:25 p.m.

TNBC Ligand-Displaying Exosomes Using RNA Nanotechnology For Targeted Cytosol Delivery Of Rnai Without Endosome Entrapment

Presented by Daniel Binzel, Ph.D., Ohio State University (MPI)
PI Dan Shu, M.D., Ohio State University
4:25–4:45 p.m.

Novel Approach To Attenuate Small Cell Lung Cancer Growth And Metastasis

Mohd Wasim Nasser, Ph.D., University of Nebraska Medical Center
4:45–5 p.m.

Q&A/Day 1 Wrap-Up

Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
Day 2: October 19, 2022
Time Session
9–10 a.m.

Join Meeting-Computer Check
10–10:10 a.m.

Day 1 Recap

Session IV: Cancer Interventions Enabled By New Material Designs (Part 2)

Moderator: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
10:10–10:30 a.m.

Development Of A Novel Biodegradable Inorganic Nanoparticle Therapeutic For Cancer

Jin Xie, Ph.D., University of Georgia
10:30–10:50 a.m.

The Development Of Novel Radiation-Sensitizer Based On Ultra-Small Carbon Dots

Zibo Li , Ph.D., University of North Carolina, Chapel Hill
10:50–11:10 a.m.

Stimuli-Responsive Mucin1-Specific Nanoparticles For Efficacious Combinatorial Chemotherapy Of Pancreatic Ductal Adenocarcinoma

Juan Luis Vivero-Escoto, Ph.D., University of North Carolina, Charlotte
11:10–11:30 a.m.

Nanotechnology For Targeted Therapy And Fundamental Understanding Of
Therapeutic Resistance In Triple Negative Breast Cancer

Xiaoming He, Ph.D., University of Maryland, College Park
11:30–11:50 a.m.

Map Leukemia-Immune Cell Talks With Nanoplasmon Ruler In CAR T-Cell Immunotherapy

Presented by Pengyu Chen, Ph.D., Auburn University (MPI)
PI Weiqiang Chen, Ph.D., New York University
11:50–12:20 p.m.

Lunch Break

Session V: Panel Discussion: Can Nanotechnology Aid In Combating Cancer Metastasis?

Moderator: Patricia Steeg, Ph.D., Center For Cancer Research, NCI
12:20–1:20 p.m.

Panel:

  • Hannah Linden, M.D., F.A.C.P., Fred Hutchinson Cancer Research Center
  • Wasim Nasser, Ph.D., University of Nebraska Medical Center
  • Baran Sumer, M.D., F.A.C.S., UT Southwestern Medical Center

Session VI: Immunotherapies And Vaccines

Moderator: Leela Rani Avula, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
1:20–1:40 p.m.

A Cobalt Porphyrin Nanoliposome Adjuvant For MHC-I-Restricted Cancer Peptide Vaccines

Jonathan Lovell, Ph.D., State University of New York at Buffalo
1:40–2 p.m.

Innovative Research For Cancer Nanotechnology (IRCN) For Enhancing Melanoma-Specific Immune Responses By The Rational Design Of Spherical Nucleic Acids

Presented by Bin Zhang, M.D., Ph.D., Northwestern University (MPI)
PI Chad Mirkin, Ph.D., Northwestern University
2–2:20 p.m.

Targeting Effector Immune Cells To Cancer With Chemically Self-Assembled Nanorings (CSANs)

Carston Wagner, Ph.D., University Of Minnesota
2:20–2:40 p.m.

Break
2:40–3 p.m.

Toward Translation Of An Immunotherapeutic Nanomedicine For Neuroblastoma

John Tanner Wilson, Ph.D., Vanderbilt University
3–3:20 p.m.

Whitlockite Nanoparticle-Based Immunotherapy For Bone Metastasis

Presented by Hae Lin Jang, Ph.D., Brigham And Women's Hospital (MPI)
PI Shiladitya Sengupta, Ph.D., Brigham And Women's Hospital
3:20–3:40 p.m.

Toward Translation Of A Plant Virus-Based In Situ Vaccination Nanotechnology

Nicole Franziska Steinmetz, Ph.D., University Of California, San Diego
3:40–4 p.m.

Closing Remarks

Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI

 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “2022 Alliance for Nanotechnology in Cancer Principal Investigators’ Meeting was originally published by the National Cancer Institute.”

Email